eIF

eIF製品

All (28)
eIF阻害剤 (13)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S2923	Salubrinal	Salubrinal is a selective inhibitor of eIF2α dephosphorylation and inhibits ER stress-mediated apoptosis with EC50 of ~15 μM in a cell-free assay.	Cell Discov, 2025, 11(1):80 Cell Metab, 2025, 37(8):1715-1731.e11 EMBO J, 2025, 44(4):1107-1130
S7369	4EGI-1	4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with K_D of 25 μM. 4EGI-1 specifically inhibits the function of mTOR by blocking the activation of 4E-BP1. 4EGI-1 induces apoptosis.	Nat Commun, 2024, 15(1):4083 Nat Commun, 2024, 15(1):4083 Nucleic Acids Res, 2024, gkae849
S0706	ISRIB	ISRIB is an integrated stress response (ISR) inhibitor that potently reverses the effects of eukaryotic initiation factor 2α (eIF2α) phosphorylation.	EMBO J, 2025, 44(4):1107-1130 Cell Death Dis, 2025, 16(1):190 Cancer Cell Int, 2025, 25(1):245
S8275	Tomivosertib (eFT-508)	Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.	Nat Commun, 2024, 15(1):9755 Nat Commun, 2024, 15(1):9755 J Clin Invest, 2024, 134(16)e168393
S7370	4E1RCat	4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E.	Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221 Cell Chem Biol, 2021, S2451-9456(21)00213-0 J Cell Mol Med, 2021, 10.1111/jcmm.16307
S7437	Sal003	Sal003 is a potent and cell-permeable eIF-2α phosphatase inhibitor.	Front Pharmacol, 2023, 14:1095307 bioRxiv, 2023, 2023.05.19.540602 bioRxiv, 2023, 2023.05.19.540602
S7428	Rocaglamide	Rocaglamide (Roc-A), isolated from Aglaia species, is a potent inhibitor of heat shock factor 1 (HSF1) activation with IC50 of ~50 nM for HSF1. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also inhibits NF-κB activity. Rocaglamide exhibits anti-tumor activity.	Life Sci Alliance, 2024, 7(9)e202302396 Elife, 2023, 12e69521 Blood Adv, 2023, 7(12):2926-2937
S9668	PKR-IN-C16	PKR-IN-C16 (C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.	Immunity, 2025, 58(10):2489-2504.e8 Exp Mol Med, 2024, 56(2):408-421. EMBO J, 2024, 43(5):780-805.
S8181	SBI-0640756	SBI-0640756(SBI-756) is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. It can also suppress AKT and NF-κB signaling.	Neoplasia, 2024, 60:101109 Sci Rep, 2021, 11(1):21689
F0316	eIF2α Antibody [C14N24]	eIF2α Rabbit mAb recognizes endogenous levels of total eIF2α protein.
F0257	Phospho-eIF2α (Ser51) Antibody [F15N7]	Phospho-eIF2α (Ser51) Rabbit mAb recognizes endogenous levels of total Phospho-eIF2α (Ser51) protein.
F0128	4E-BP1 Antibody [H19K14]	4E-BP1 Rabbit mAb recognizes endogenous levels of total 4E-BP1 protein.
F0562	eIF4E Antibody [E22A18]	eIF4E Rabbit mAb detects endogenous levels of total eIF4E protein. This antibody does not cross-react with 4EHP protein.
F0851^New	Phospho-4E-BP1 (Thr70) Antibody [K18C18]	Phospho-4E-BP1 (Thr70) Rabbit mAb recognizes endogenous levels of 4E-BP1 protein only when phosphorylated at Ser70.
F0614	eIF4G Antibody [B24F24]	eIF4G Rabbit mAb is produced by immunizing rabbits with a synthetic peptide corresponding to residues surrounding Gly188 of human eIF4G.
F1674	Phospho-eIF4E (Ser209) Antibody [N23E19]
F3063	eIF4A Antibody [A24J8]
F0666	eIF3A Antibody [M19A24]
F0919	eIF4GI Antibody [B12F2]
F1432	eIF4G2/p97 Antibody [P17K12]
F0585	Non-phospho 4E-BP1 (Thr46) Antibody [L9H10]
F1305	Phospho-eIF4B (Ser406) Antibody [B22D6]
F1420	eIF3H Antibody [E24C7]
F1481	eIF4H Antibody [N12E11]
E4888	Guanabenz hydrochloride	Guanabenz hydrochloride(NE56490) is a small molecule, antihypertensive agonist of α2-adrenoceptor. It also inhibits eIF2α and GADD34, showing potential for treating cardiac hypertrophy, heart failure, atherosclerosis, and ischemic heart disease.
S6533	Briciclib	Briciclib (ON-014185) is a water soluble derivative of ON-013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E).
S8994	Zotatifin	Zotatifin (eFT226) is a highly effective and sequence-selective inhibitor of the RNA helicase eIF4A. It promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5'-UTRs, with an IC50 of 2 nM, and disrupts the assembly of the eIF4F initiation complex. By enhancing the interaction between eIF4A and polypurine RNA sequence or structural motifs, zotatifin converts eIF4A into a sequence-specific translation repressor, thereby regulating the translation of certain target genes. It also exhibits anti-tumor activity.
S2961	GC7 Sulfate	GC7 (N1-guanyl-1,7-diaminoheptane) Sulfate is an inhibitor of deoxyhypusine synthase (DHPS). GC7 inhibits Neuroblastoma (NB) cell proliferation in a dose-dependent manner, through induction of the cell cycle inhibitor p21 and reduction of total and phosphorylated Rb proteins.	Exp Mol Med, 2024, 10.1038/s12276-024-01214-1
S2923	Salubrinal	Salubrinal is a selective inhibitor of eIF2α dephosphorylation and inhibits ER stress-mediated apoptosis with EC50 of ~15 μM in a cell-free assay.	Cell Discov, 2025, 11(1):80 Cell Metab, 2025, 37(8):1715-1731.e11 EMBO J, 2025, 44(4):1107-1130
S7369	4EGI-1	4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with K_D of 25 μM. 4EGI-1 specifically inhibits the function of mTOR by blocking the activation of 4E-BP1. 4EGI-1 induces apoptosis.	Nat Commun, 2024, 15(1):4083 Nat Commun, 2024, 15(1):4083 Nucleic Acids Res, 2024, gkae849
S0706	ISRIB	ISRIB is an integrated stress response (ISR) inhibitor that potently reverses the effects of eukaryotic initiation factor 2α (eIF2α) phosphorylation.	EMBO J, 2025, 44(4):1107-1130 Cell Death Dis, 2025, 16(1):190 Cancer Cell Int, 2025, 25(1):245
S8275	Tomivosertib (eFT-508)	Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.	Nat Commun, 2024, 15(1):9755 Nat Commun, 2024, 15(1):9755 J Clin Invest, 2024, 134(16)e168393
S7370	4E1RCat	4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E.	Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221 Cell Chem Biol, 2021, S2451-9456(21)00213-0 J Cell Mol Med, 2021, 10.1111/jcmm.16307
S7437	Sal003	Sal003 is a potent and cell-permeable eIF-2α phosphatase inhibitor.	Front Pharmacol, 2023, 14:1095307 bioRxiv, 2023, 2023.05.19.540602 bioRxiv, 2023, 2023.05.19.540602
S7428	Rocaglamide	Rocaglamide (Roc-A), isolated from Aglaia species, is a potent inhibitor of heat shock factor 1 (HSF1) activation with IC50 of ~50 nM for HSF1. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also inhibits NF-κB activity. Rocaglamide exhibits anti-tumor activity.	Life Sci Alliance, 2024, 7(9)e202302396 Elife, 2023, 12e69521 Blood Adv, 2023, 7(12):2926-2937
S9668	PKR-IN-C16	PKR-IN-C16 (C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.	Immunity, 2025, 58(10):2489-2504.e8 Exp Mol Med, 2024, 56(2):408-421. EMBO J, 2024, 43(5):780-805.
S8181	SBI-0640756	SBI-0640756(SBI-756) is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. It can also suppress AKT and NF-κB signaling.	Neoplasia, 2024, 60:101109 Sci Rep, 2021, 11(1):21689
E4888	Guanabenz hydrochloride	Guanabenz hydrochloride(NE56490) is a small molecule, antihypertensive agonist of α2-adrenoceptor. It also inhibits eIF2α and GADD34, showing potential for treating cardiac hypertrophy, heart failure, atherosclerosis, and ischemic heart disease.
S6533	Briciclib	Briciclib (ON-014185) is a water soluble derivative of ON-013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E).
S8994	Zotatifin	Zotatifin (eFT226) is a highly effective and sequence-selective inhibitor of the RNA helicase eIF4A. It promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5'-UTRs, with an IC50 of 2 nM, and disrupts the assembly of the eIF4F initiation complex. By enhancing the interaction between eIF4A and polypurine RNA sequence or structural motifs, zotatifin converts eIF4A into a sequence-specific translation repressor, thereby regulating the translation of certain target genes. It also exhibits anti-tumor activity.
S2961	GC7 Sulfate	GC7 (N1-guanyl-1,7-diaminoheptane) Sulfate is an inhibitor of deoxyhypusine synthase (DHPS). GC7 inhibits Neuroblastoma (NB) cell proliferation in a dose-dependent manner, through induction of the cell cycle inhibitor p21 and reduction of total and phosphorylated Rb proteins.	Exp Mol Med, 2024, 10.1038/s12276-024-01214-1
F0851^New	Phospho-4E-BP1 (Thr70) Antibody [K18C18]	Phospho-4E-BP1 (Thr70) Rabbit mAb recognizes endogenous levels of 4E-BP1 protein only when phosphorylated at Ser70.